1. Home
  2. ALLO vs NVX Comparison

ALLO vs NVX Comparison

Compare ALLO & NVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$1.80

Market Cap

252.9M

Sector

Health Care

ML Signal

HOLD

Logo NOVONIX Limited American Depository Shares

NVX

NOVONIX Limited American Depository Shares

HOLD

Current Price

$0.90

Market Cap

235.2M

Sector

Miscellaneous

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALLO
NVX
Founded
2017
2012
Country
United States
Australia
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Industrial Machinery/Components
Sector
Health Care
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
252.9M
235.2M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
ALLO
NVX
Price
$1.80
$0.90
Analyst Decision
Strong Buy
Analyst Count
12
0
Target Price
$8.27
N/A
AVG Volume (30 Days)
6.3M
1.2M
Earning Date
03-12-2026
01-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$5,931,433.00
Revenue This Year
N/A
$165.90
Revenue Next Year
N/A
$1,344.85
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.86
$0.81
52 Week High
$3.78
$3.86

Technical Indicators

Market Signals
Indicator
ALLO
NVX
Relative Strength Index (RSI) 58.49 38.18
Support Level $1.56 $0.83
Resistance Level $1.84 $0.97
Average True Range (ATR) 0.16 0.06
MACD -0.01 -0.01
Stochastic Oscillator 67.96 19.81

Price Performance

Historical Comparison
ALLO
NVX

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About NVX NOVONIX Limited American Depository Shares

NOVONIX Ltd operates in the lithium-ion battery industry. The company has three operating segments namely Graphite Exploration, Battery Technology, and Battery Materials. Graphite Exploration segment is engaged in the exploration and development of high-grade flake graphite deposits. The Battery Technology segment develops battery cell testing equipment and carries out research and development in battery development. The Battery Materials segment develops and manufactures battery anode materials. The Battery Technology segment generates maximum revenue for the company.

Share on Social Networks: